Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses ILMN in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ILMN in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jacob Thaysen | $1,000,000 | $0 | $8,763,122 | $0 | $1,155,000 | $0 | $100,773 | $11,018,895 |
| Chief Executive Officer | ||||||||
| Everett Cunningham | 650,000 | 500,000 | 2,871,220 | 0 | 0 | 0 | 65,881 | 4,087,101 |
| Former Chief Commercial Officer | ||||||||
| Ankur Dhingra | 650,000 | 0 | 3,092,079 | 0 | 325,325 | 0 | 10,667 | 4,078,071 |
| Chief Financial Officer | ||||||||
| Steve Barnard | 600,000 | 0 | 2,562,176 | 0 | 300,300 | 0 | 17,676 | 3,480,152 |
| Chief Technology Officer | ||||||||
| Kevin Pegels | 575,000 | 0 | 2,297,028 | 0 | 287,788 | 0 | 20,204 | 3,180,020 |
| Chief of Global Operations | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Jacob Thaysen | $11,018,895 | $14,802,924 | $4,691,233 | −3,784,029 |
| Everett Cunningham | 4,087,101 | 10,073,818 | — | −5,986,717 |
| Ankur Dhingra | 4,078,071 | 5,856,087 | — | −1,778,016 |
| Steve Barnard | 3,480,152 | 4,020,936 | — | −540,784 |
| Kevin Pegels | 3,180,020 | 3,849,842 | — | −669,822 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Christensen Jakob Wedel | SVP, Strategy/Corp Development | 2026-05-05 | D | 700 | $139 | $97,328 | Common | Form 4 ↗ |
| Christensen Jakob Wedel | SVP, Strategy/Corp Development | 2026-05-05 | D | 233 | 139 | 32,403 | Common | Form 4 ↗ |
| Keith Meister | Director | 2026-05-07 | A | 9,236 | 103 | 949,646 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-07 | D | 79,568 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Keith Meister | Director | 2026-05-07 | A | 79,568 | 103 | 8,181,182 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-07 | D | 9,236 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Keith Meister | Director | 2026-05-07 | D | 79,568 | 143 | 11,414,030 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-07 | D | 9,236 | 140 | 1,295,349 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-12 | D | 180 | 148 | 26,604 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-12 | D | 12,309 | 144 | 1,774,096 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-12 | D | 5,310 | 148 | 786,623 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-12 | D | 255,378 | 145 | 36,942,981 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-12 | D | 6,524 | 148 | 962,290 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-12 | D | 255,378 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Keith Meister | Director | 2026-05-12 | D | 53,610 | 146 | 7,823,843 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-12 | A | 255,378 | 103 | 26,257,966 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-12 | D | 159,623 | 145 | 23,186,837 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-12 | D | 25,352 | 146 | 3,705,195 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-12 | D | 13,776 | 147 | 2,024,521 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-12 | D | 52,776 | 145 | 7,641,965 | Common, indirect | Form 4 ↗ |
| Caroline Dorsa | Director | 2026-05-20 | D | 1,512 | 142 | 214,583 | Common | Form 4 ↗ |
| Caroline Dorsa | Director | 2026-05-20 | A | 2,072 | 145 | 300,088 | Common | Form 4 ↗ |
| David King | Director | 2026-05-21 | A | 2,072 | 145 | 300,088 | Common | Form 4 ↗ |
| Philip Schiller | Director | 2026-05-21 | A | 2,072 | 145 | 300,088 | Common | Form 4 ↗ |
| Scott Gottlieb | Director | 2026-05-21 | A | 2,072 | 145 | 300,088 | Common | Form 4 ↗ |
| Susan Siegel | Director | 2026-05-21 | A | 2,072 | 145 | 300,088 | Common | Form 4 ↗ |
| Keith Meister | Director | 2026-05-21 | A | 2,072 | 145 | 300,088 | Common | Form 4 ↗ |
| Anna Richo | Director | 2026-05-21 | A | 2,072 | 145 | 300,088 | Common | Form 4 ↗ |
| Scott Ullem | Director | 2026-05-21 | A | 2,072 | 145 | 300,088 | Common | Form 4 ↗ |
| Keith Meister | Director | 2026-05-28 | D | 6,888 | 165 | 1,134,798 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-28 | D | 63,020 | 163 | 10,263,437 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-28 | D | 61,613 | 164 | 10,077,422 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-28 | D | 11,760 | 160 | 1,876,543 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-28 | D | 4,579 | 161 | 734,930 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-28 | D | 6,198 | 164 | 1,016,286 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-28 | D | 70,262 | 162 | 11,411,251 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-28 | D | 87,653 | 164 | 14,404,894 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-28 | D | 24,562 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott D. Ericksen | VP, Chief Accounting Officer | 2026-05-28 | D | 500 | 160 | 80,000 | Common | Form 4 ↗ |
| Keith Meister | Director | 2026-05-28 | D | 37,590 | 157 | 5,882,835 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-28 | D | 110,424 | 148 | 16,287,540 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-28 | D | 24,562 | 156 | 3,841,497 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-28 | D | 71,986 | 157 | 11,329,157 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-28 | D | 5,256 | 162 | 849,580 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-28 | D | 19,832 | 164 | 3,243,920 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-28 | D | 92,877 | 165 | 15,283,839 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-28 | D | 15,472 | 166 | 2,560,616 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-28 | A | 24,562 | 103 | 2,525,465 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-28 | D | 1,961 | 165 | 324,153 | Common, indirect | Form 4 ↗ |
| Scott D. Ericksen | VP, Chief Accounting Officer | 2026-05-28 | D | 1,500 | 150 | 225,150 | Common | Form 4 ↗ |
| Keith Meister | Director | 2026-05-28 | D | 2,225 | 162 | 361,429 | Common, indirect | Form 4 ↗ |
| Scott M. Davies | Chief Legal Officer | 2026-05-29 | D | 615 | 160 | 98,400 | Common | Form 4 ↗ |
| Patricia Leckman | SVP, Chief People Officer | 2026-06-02 | D | 290 | 163 | 47,276 | Common, open-market sale | Form 4 ↗ |
| Patricia Leckman | SVP, Chief People Officer | 2026-06-02 | D | 318 | 162 | 51,516 | Common, open-market sale | Form 4 ↗ |
| Patricia Leckman | SVP, Chief People Officer | 2026-06-02 | D | 176 | 161 | 28,276 | Common, open-market sale | Form 4 ↗ |
| Patricia Leckman | SVP, Chief People Officer | 2026-06-05 | D | 39 | 165 | 6,428 | Common | Form 4 ↗ |
| Patricia Leckman | SVP, Chief People Officer | 2026-06-05 | D | 374 | 163 | 60,880 | Common, open-market sale | Form 4 ↗ |
| Patricia Leckman | SVP, Chief People Officer | 2026-06-05 | D | 2 | 168 | 336 | Common | Form 4 ↗ |
| Patricia Leckman | SVP, Chief People Officer | 2026-06-05 | D | 78 | 163 | 12,742 | Common, open-market sale | Form 4 ↗ |
| Patricia Leckman | SVP, Chief People Officer | 2026-06-05 | D | 290 | 162 | 46,919 | Common, open-market sale | Form 4 ↗ |
| Daniel Skovronsky | Director | 2026-06-16 | A | 1,674 | 164 | 275,005 | Common | Form 4 ↗ |
| Scott M. Davies | Chief Legal Officer | 2026-06-25 | D | 615 | 180 | 110,700 | Common | Form 4 ↗ |
| Keith Meister | Director | 2026-06-30 | A | 142 | 149 | 21,185 | Common | Form 4 ↗ |
| Scott Ullem | Director | 2026-06-30 | A | 167 | 149 | 24,914 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Kevin Pegels | RSU | — | — | — | 7,283 | — | $624,080 |
| Ankur Dhingra | PSU | — | 5,719 | 11,437 | — | 28,593 | 1,272,023 |
| Everett Cunningham | PSU | — | 5,310 | 10,620 | — | 26,550 | 910,028 |
| Ankur Dhingra | RSU | — | — | — | 9,803 | — | 840,019 |
| Steve Barnard | PSU | — | 4,739 | 9,477 | — | 23,693 | 1,054,032 |
| Steve Barnard | RSU | — | — | — | 8,123 | — | 696,060 |
| Steve Barnard | PSU | — | 4,739 | 9,477 | — | 23,693 | 812,084 |
| Kevin Pegels | PSU | — | 4,248 | 8,496 | — | 21,240 | 944,925 |
| Kevin Pegels | PSU | — | 4,248 | 8,496 | — | 21,240 | 728,023 |
| Everett Cunningham | PSU | — | 5,310 | 10,620 | — | 26,550 | 1,181,156 |
| Jacob Thaysen | PSU | — | 16,747 | 33,493 | — | 83,733 | 2,870,015 |
| Jacob Thaysen | RSU | — | — | — | 28,709 | — | 2,460,074 |
| Everett Cunningham | RSU | — | — | — | 9,103 | — | 780,036 |
| Ankur Dhingra | PSU | — | 5,719 | 11,437 | — | 28,593 | 980,037 |
| Jacob Thaysen | PSU | — | 16,747 | 33,493 | — | 83,733 | 3,433,033 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Kevin Pegels | $624,080 | $1,672,948 | $0 | 72.8% |
| Ankur Dhingra | 840,019 | 2,252,060 | 0 | 72.8% |
| Everett Cunningham | 780,036 | 2,091,184 | 0 | 72.8% |
| Steve Barnard | 696,060 | 1,866,116 | 0 | 72.8% |
| Jacob Thaysen | 2,460,074 | 6,303,048 | 0 | 71.9% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Ankur Dhingra | RSU | 9,803 | — | $1,322,915 |
| Steve Barnard | RSU | 12,554 | — | 1,694,162 |
| Steve Barnard | RSU | 706 | — | 95,275 |
| Jacob Thaysen | RSU | 45,750 | — | 6,173,963 |
| Everett Cunningham | RSU | 27,645 | — | 3,730,693 |
| Everett Cunningham | PSU | 18,430 | — | 2,487,129 |
| Jacob Thaysen | RSU | 7,575 | — | 1,022,246 |
| Steve Barnard | PSU | 6,893 | — | 930,210 |
| Ankur Dhingra | RSU | 6,752 | — | 911,182 |
| Kevin Pegels | PSU | 6,627 | — | 894,314 |
| Kevin Pegels | RSU | 1,284 | — | 173,276 |
| Steve Barnard | PSU | 9,477 | — | 1,278,921 |
| Jacob Thaysen | RSU | 2,560 | — | 345,472 |
| Steve Barnard | RSU | 1,600 | — | 215,920 |
| Kevin Pegels | PSU | 8,496 | — | 1,146,535 |
| Everett Cunningham | PSU | 10,620 | — | 1,433,169 |
| Jacob Thaysen | PSU | 33,493 | — | 4,519,880 |
| Ankur Dhingra | PSU | 11,437 | — | 1,543,423 |
| Jacob Thaysen | PSU | 26,508 | — | 3,577,255 |
| Kevin Pegels | RSU | 11,543 | — | 1,557,728 |
| Ankur Dhingra | PSU | 10,502 | — | 1,417,245 |
| Everett Cunningham | RSU | 9,103 | — | 1,228,450 |
Illumina's compensation philosophy is designed to achieve four objectives: (1) Pay for Performance — linking compensation with short-, mid- and long-term performance; (2) Align Interests — strengthening the relationship between pay and stockholder value with best-in-class governance; (3) Competitive Rewards — rewarding individuals for creating sustainable stockholder value at industry-competitive levels; and (4) Retention — attracting, retaining, and rewarding world-class executives. Over 80% of executive officer target direct compensation is at risk.
| CEO STI target (% of salary) | 150% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon (Aon's Human Capital Practice, a division of Aon, plc) |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-21 | 121,746,792 | 8,464,596 | 404,097 | 93.5% | Passed |
| 2025 | 2025-05-21 | 115,560,563 | 11,450,964 | 3,517,311 | 90.98% | Passed |
| 2024 | 2024-05-16 | 113,511,456 | 16,719,619 | 1,063,352 | 86.46% | Passed |
| 2023 | 2023-05-25 | 18,170,980 | 109,292,943 | 3,532,713 | 13.87% | Failed |
| 2022 | 2022-05-26 | 107,207,988 | 22,804,135 | 637,007 | 82.06% | Passed |
| 2021 | 2021-05-26 | 102,299,770 | 22,746,808 | 158,172 | 81.71% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-21 | 93.5%a |
| 2025 | 2025-05-21 | 90.98%b |
| 2024 | 2024-05-16 | 86.46%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast either "FOR" or "AGAINST" and will have no effect on the outcome of this proposal but will be counted only for purposes of determining whether a quorum is present at the annual meeting.”.
b. Approved under the standard stated in the filing — “As noted above, under our bylaws, except in certain circumstances, abstentions are not counted as votes cast either "for" or "against", and thus the vote required for approval of Proposal 3 is the majority of votes cast (meaning the number of stocks voted "for" a matter must exceed the number of stocks voted "against" such matter, with abstentions and broker non-votes not counted as votes cast either "for" or "against" such matter).”.
c. Approved under the standard stated in the filing — “rson or represented by proxy and entitled to vote on the proposal must vote FOR in order for this proposal to pass FOR AGAINST ABSTAIN If you abstain from voting on this proposal, the abstention will have the same effect as an "AGAINST" vote FOR Proposal 3 -- Advisory vote to approve the compensation provided to our "named executive officers" as disclosed in this proxy statement Majority of the shares present in person or represented by proxy and entitled to vote on the proposal must vote FOR in order for this proposal to pass FOR AGAINST ABSTAIN If you abstain from voting on this proposal, the abstention will have the same effect as an "AGAINST" vote FOR 88 • Illumina, Inc.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 97 : 1 |
|---|---|
| CEO total compensation | $11,018,895 |
| Median employee compensation | $113,021 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Scott GottliebIndependent · Board Chair · Nominating/Corporate Governance | $160,338 | $300,019 | $0 | $0 | $0 | $460,357 |
| Keith MeisterIndependent · Nominating/Corporate Governance | 61,096 | 350,019 | 0 | 0 | 0 | 411,115 |
| Frances ArnoldIndependent · Nominating/Corporate Governance · Science and Technology (Chair) · Not standing for re-election | 105,000 | 300,019 | 0 | 0 | 0 | 405,019 |
| Caroline DorsaIndependent · Audit · Compensation | 104,492 | 300,019 | 0 | 0 | 0 | 404,511 |
| Susan SiegelIndependent · Compensation (Chair) | 100,000 | 300,019 | 0 | 0 | 0 | 400,019 |
| Robert EpsteinIndependent · Compensation · Nominating/Corporate Governance · Not standing for re-election | 100,000 | 300,019 | 0 | 0 | 0 | 400,019 |
| Gary GuthartIndependent · Audit · Science and Technology · Not standing for re-election | 100,000 | 300,019 | 0 | 0 | 0 | 400,019 |
| Scott UllemIndependent · Audit (Chair) | 99,080 | 300,019 | 0 | 0 | 0 | 399,099 |
| Philip SchillerIndependent · Nominating/Corporate Governance · Science and Technology | 95,000 | 300,019 | 0 | 0 | 0 | 395,019 |
| Anna RichoIndependent · Nominating/Corporate Governance (Chair) | 86,415 | 300,019 | 0 | 0 | 0 | 386,434 |
| Stephen MacMillanIndependent · Departed during FY | 46,250 | — | 0 | 0 | 0 | 46,250 |
| David KingIndependent · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Jacob ThaysenEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $75,000 |
|---|---|
| Annual equity retainer | $300,019 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 100,000 / 100,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $1,057,671 |
| Equity awards (grant-date value) | $3,050,190 |
| All other compensation | $0 |
| Total cost of the board | $4,107,861 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Illumina, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Illumina, Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Biogen Inc. | 2025 | Christopher Viehbacher | $1,727,885 | $18,368,875 | $0 | $3,190,875 | $23,646,004 |
| 2 | Vertex Pharmaceuticals, Inc. | 2025 | Reshma Kewalramani | 1,600,000 | 15,002,270 | 0 | 4,118,640 | 21,144,261 |
| 3 | Intuitive Surgical, Inc. | 2025 | David Rosa | 858,750 | 18,674,872 | 0 | 1,373,859 | 20,997,480 |
| 4 | Align Technology, Inc. | 2025 | Joseph Hogan | 1,400,000 | 16,556,872 | 0 | 1,220,100 | 19,193,988 |
| 5 | Jazz Pharmaceuticals plc | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 6 | Edwards Lifesciences Corporation | 2025 | Bernard Zovighian | 1,192,500 | 7,167,024 | 6,499,109 | 2,406,537 | 17,454,255 |
| 7 | The Cooper Companies, Inc. | 2025 | Albert White III | 1,170,769 | 6,642,918 | 6,643,050 | 1,525,951 | 16,051,141 |
| 8 | Hologic, Inc. | 2024 | Stephen MacMillan | 1,212,628 | 9,141,468 | 2,937,477 | 1,990,413 | 15,819,261 |
| 9 | IDEXX Laboratories, Inc. | 2025 | Jonathan Mazelsky | 1,150,000 | 5,399,881 | 5,400,001 | 2,593,000 | 14,580,122 |
| 10 | Waters Corporation | 2025 | Udit Batra | 1,150,000 | 7,430,247 | 2,999,922 | 2,371,875 | 13,973,044 |
| 11 | GeneDx Holdings Corp. | 2025 | Katherine Stueland | 715,869 | 11,738,600 | 0 | 1,075,500 | 13,547,219 |
| 12 | Agilent Technologies, Inc. | 2025 | Padraig McDonnell | 1,141,345 | 8,169,850 | 2,017,759 | 1,436,809 | 12,827,236 |
| 13 | Illumina, Inc. | 2025 | Jacob Thaysen | 1,000,000 | 8,763,122 | 0 | 1,155,000 | 11,018,895 |
| 14 | Bio-Rad Laboratories, Inc. | 2025 | Norman Schwartz | 1,089,877 | 4,856,574 | 1,458,975 | 562,088 | 7,995,841 |
| 15 | DexCom, Inc. | 2025 | Jacob Leach | 768,962 | 5,936,062 | 0 | 1,164,780 | 7,985,960 |
| 16 | Regeneron Pharmaceuticals, Inc. | 2025 | Leonard Schleifer | 1,979,922 | 0 | 0 | 3,682,655 | 7,280,549 |
| 17 | West Pharmaceutical Services, Inc | 2025 | Eric Green | 1,177,290 | 3,327,048 | 1,108,961 | 1,471,613 | 7,190,876 |
| 18 | Mettler-Toledo International Inc. | 2025 | Patrick Kaltenbach | 1,145,999 | 3,267,808 | 1,635,033 | 462,984 | 6,741,212 |
| 19 | Vestis Corporation | 2025 | James Barber | 292,308 | 2,937,800 | 0 | 0 | 3,288,352 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Illumina, Inc. | 1155% | not disclosed | Yes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology Index | Aon (Aon's Human Capital Practice, a division of Aon, plc) |
| Agilent Technologies, Inc. | not disclosed | PSU 60 · Options 20 · RSU 20 | No | Semler Brossy |
| Align Technology, Inc. | 58.1% | MSU 70 · RSU 30 | Yes — Relative Total Stockholder Return (TSR) vs. Nasdaq Composite Index | Compensia, Inc. |
| Bio-Rad Laboratories, Inc. | not disclosed | not disclosed | not disclosed | Compensia, Inc. |
| Biogen Inc. | 127% | PSU 60 · RSU 40 | Yes | Pay Governance |
| DexCom, Inc. | not disclosed | not disclosed | Yes — Relative TSR Performance Metric | Aon Hewitt Consulting Company |
| Edwards Lifesciences Corporation | 127% | Options 50 · PSU 25 · RSU 25 | No | Semler Brossy Consulting Group |
| GeneDx Holdings Corp. | 150% | PSU 50 · RSU 50 | No | Pearl Meyer |
| Hologic, Inc. | 109% | PSU 50 · RSU 25 · Options 25 | No | not disclosed |
| IDEXX Laboratories, Inc. | 140% | Options 50 · PSU 50 | No | Farient |
| Intuitive Surgical, Inc. | 115.2% | RSU 50 · PSU 50 | No | Aon |
| Jazz Pharmaceuticals plc | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Mettler-Toledo International Inc. | 80% | PSU 33 · RSU 33 · Options 33 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners (PM&P) |
| Regeneron Pharmaceuticals, Inc. | 155% | Options 60 · RSA 40 | not disclosed | Pay Governance LLC |
| The Cooper Companies, Inc. | 100.9% | Options 50 · PSU 50 | No | Compensia |
| Vertex Pharmaceuticals, Inc. | not disclosed | PSU 55 · RSU 45 | No | not disclosed |
| Vestis Corporation | not disclosed | not disclosed | not disclosed | not disclosed |
| Waters Corporation | 110% | PSU 50 · Options 35 · RSU 15 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer |
| West Pharmaceutical Services, Inc | 100% | PSU 50 · RSU 25 · Options 25 | No | Pay Governance |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Jacob Thaysen | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Summary Compensation Table”. As printed: 11,018,895. Filing ↗machine: r4 · c14 · span 728526–728536 |
| 2 | Section 01, Everett Cunningham | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Summary Compensation Table”. As printed: 4,087,101. Filing ↗machine: r22 · c14 · span 745460–745469 |
| 3 | Section 01, Ankur Dhingra | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Summary Compensation Table”. As printed: 4,078,071. Filing ↗machine: r10 · c14 · span 734054–734063 |
| 4 | Section 01, Steve Barnard | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Summary Compensation Table”. As printed: 3,480,152. Filing ↗machine: r14 · c14 · span 738033–738042 |
| 5 | Section 01, Kevin Pegels | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Summary Compensation Table”. As printed: 3,180,020. Filing ↗machine: r18 · c14 · span 741451–741460 |
| 6 | Section 03, Kevin Pegels RSU | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r35 · c20 · span 795955–795962 |
| 7 | Section 03, Ankur Dhingra PSU | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r15 · c20 · span 774816–774825 |
| 8 | Section 03, Everett Cunningham PSU | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r41 · c20 · span 802397–802404 |
| 9 | Section 03, Ankur Dhingra RSU | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r19 · c20 · span 778978–778985 |
| 10 | Section 03, Steve Barnard PSU | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r23 · c20 · span 783307–783316 |
| 11 | Section 03, Steve Barnard RSU | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r27 · c20 · span 787520–787527 |
| 12 | Section 03, Steve Barnard PSU | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r25 · c20 · span 785413–785420 |
| 13 | Section 03, Kevin Pegels PSU | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r31 · c20 · span 791796–791803 |
| 14 | Section 03, Kevin Pegels PSU | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r33 · c20 · span 793855–793862 |
| 15 | Section 03, Everett Cunningham PSU | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r39 · c20 · span 800290–800299 |
| 16 | Section 03, Jacob Thaysen PSU | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r9 · c20 · span 768426–768435 |
| 17 | Section 03, Jacob Thaysen RSU | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r11 · c20 · span 770536–770545 |
| 18 | Section 03, Everett Cunningham RSU | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r43 · c20 · span 804504–804511 |
| 19 | Section 03, Ankur Dhingra PSU | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r17 · c20 · span 776878–776885 |
| 20 | Section 03, Jacob Thaysen PSU | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t132 · r7 · c20 · span 766318–766327 |
| 21 | Section 07, pay ratio | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “CEO Pay Ratio”. As printed: 97 : 1. Filing ↗machine: span 923878–923880 |
| 22 | Section 08, Scott Gottlieb | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Director Compensation”. As printed: 460,357. Filing ↗machine: t58 · r4 · c14 · span 436541–436548 |
| 23 | Section 08, Keith Meister | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Director Compensation”. As printed: 411,115. Filing ↗machine: t58 · r14 · c14 · span 443483–443490 |
| 24 | Section 08, Frances Arnold | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Director Compensation”. As printed: 405,019. Filing ↗machine: t58 · r6 · c14 · span 437939–437946 |
| 25 | Section 08, Caroline Dorsa | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Director Compensation”. As printed: 404,511. Filing ↗machine: t58 · r8 · c14 · span 439287–439294 |
| 26 | Section 08, Susan Siegel | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Director Compensation”. As printed: 400,019. Filing ↗machine: t58 · r20 · c14 · span 447570–447577 |
| 27 | Section 08, Robert Epstein | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Director Compensation”. As printed: 400,019. Filing ↗machine: t58 · r10 · c14 · span 440685–440692 |
| 28 | Section 08, Gary Guthart | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Director Compensation”. As printed: 400,019. Filing ↗machine: t58 · r12 · c14 · span 442031–442038 |
| 29 | Section 08, Scott Ullem | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Director Compensation”. As printed: 399,099. Filing ↗machine: t58 · r24 · c14 · span 450407–450414 |
| 30 | Section 08, Philip Schiller | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Director Compensation”. As printed: 395,019. Filing ↗machine: t58 · r18 · c14 · span 446224–446231 |
| 31 | Section 08, Anna Richo | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Director Compensation”. As printed: 386,434. Filing ↗machine: t58 · r16 · c14 · span 444826–444833 |
| 32 | Section 08, Stephen MacMillan | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Director Compensation”. As printed: 46,250. Filing ↗machine: t58 · r22 · c4 · span 448433–448439 |
| 33 | Section 08, David King | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 34 | Section 08, Jacob Thaysen | DEF 14A | 2026-04-09 | 0001193125-26-149669 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 35 | Section 02, Christensen Jakob Wedel 2026-05-05 | Form 4 | 2026-05-07 | 0001110803-26-000094 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Christensen Jakob Wedel 2026-05-05 | Form 4 | 2026-05-07 | 0001110803-26-000094 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Keith Meister 2026-05-07 | Form 4 | 2026-05-11 | 0001011438-26-000273 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Keith Meister 2026-05-07 | Form 4 | 2026-05-11 | 0001011438-26-000273 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Keith Meister 2026-05-07 | Form 4 | 2026-05-11 | 0001011438-26-000273 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Keith Meister 2026-05-07 | Form 4 | 2026-05-11 | 0001011438-26-000273 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Keith Meister 2026-05-07 | Form 4 | 2026-05-11 | 0001011438-26-000273 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Keith Meister 2026-05-07 | Form 4 | 2026-05-11 | 0001011438-26-000273 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Keith Meister 2026-05-12 | Form 4 | 2026-05-14 | 0001011438-26-000335 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Keith Meister 2026-05-12 | Form 4 | 2026-05-14 | 0001011438-26-000335 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Keith Meister 2026-05-12 | Form 4 | 2026-05-14 | 0001011438-26-000335 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Keith Meister 2026-05-12 | Form 4 | 2026-05-14 | 0001011438-26-000335 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Keith Meister 2026-05-12 | Form 4 | 2026-05-14 | 0001011438-26-000335 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Keith Meister 2026-05-12 | Form 4 | 2026-05-14 | 0001011438-26-000335 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Keith Meister 2026-05-12 | Form 4 | 2026-05-14 | 0001011438-26-000335 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Keith Meister 2026-05-12 | Form 4 | 2026-05-14 | 0001011438-26-000335 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Keith Meister 2026-05-12 | Form 4 | 2026-05-14 | 0001011438-26-000335 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Keith Meister 2026-05-12 | Form 4 | 2026-05-14 | 0001011438-26-000335 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Keith Meister 2026-05-12 | Form 4 | 2026-05-14 | 0001011438-26-000335 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Keith Meister 2026-05-12 | Form 4 | 2026-05-14 | 0001011438-26-000335 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Caroline Dorsa 2026-05-20 | Form 4 | 2026-05-22 | 0001110803-26-000114 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Caroline Dorsa 2026-05-20 | Form 4 | 2026-05-22 | 0001110803-26-000114 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, David King 2026-05-21 | Form 4 | 2026-05-22 | 0001110803-26-000121 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Philip Schiller 2026-05-21 | Form 4 | 2026-05-22 | 0001110803-26-000118 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Scott Gottlieb 2026-05-21 | Form 4 | 2026-05-22 | 0001110803-26-000115 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Susan Siegel 2026-05-21 | Form 4 | 2026-05-22 | 0001110803-26-000120 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Keith Meister 2026-05-21 | Form 4 | 2026-05-22 | 0001110803-26-000116 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Anna Richo 2026-05-21 | Form 4 | 2026-05-22 | 0001110803-26-000117 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Scott Ullem 2026-05-21 | Form 4 | 2026-05-22 | 0001110803-26-000119 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Keith Meister 2026-05-28 | Form 4 | 2026-06-01 | 0001011438-26-000371 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Keith Meister 2026-05-28 | Form 4 | 2026-06-01 | 0001011438-26-000371 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Keith Meister 2026-05-28 | Form 4 | 2026-06-01 | 0001011438-26-000371 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Keith Meister 2026-05-28 | Form 4 | 2026-06-01 | 0001011438-26-000371 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Keith Meister 2026-05-28 | Form 4 | 2026-06-01 | 0001011438-26-000371 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Keith Meister 2026-05-28 | Form 4 | 2026-06-01 | 0001011438-26-000371 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Keith Meister 2026-05-28 | Form 4 | 2026-06-01 | 0001011438-26-000371 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Keith Meister 2026-05-28 | Form 4 | 2026-06-01 | 0001011438-26-000371 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Keith Meister 2026-05-28 | Form 4 | 2026-06-01 | 0001011438-26-000371 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Scott D. Ericksen 2026-05-28 | Form 4 | 2026-06-01 | 0001110803-26-000129 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Keith Meister 2026-05-28 | Form 4 | 2026-06-01 | 0001011438-26-000371 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Keith Meister 2026-05-28 | Form 4 | 2026-06-01 | 0001011438-26-000371 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Keith Meister 2026-05-28 | Form 4 | 2026-06-01 | 0001011438-26-000371 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Keith Meister 2026-05-28 | Form 4 | 2026-06-01 | 0001011438-26-000371 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Keith Meister 2026-05-28 | Form 4 | 2026-06-01 | 0001011438-26-000371 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Keith Meister 2026-05-28 | Form 4 | 2026-06-01 | 0001011438-26-000371 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Keith Meister 2026-05-28 | Form 4 | 2026-06-01 | 0001011438-26-000371 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Keith Meister 2026-05-28 | Form 4 | 2026-06-01 | 0001011438-26-000371 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Keith Meister 2026-05-28 | Form 4 | 2026-06-01 | 0001011438-26-000371 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Keith Meister 2026-05-28 | Form 4 | 2026-06-01 | 0001011438-26-000371 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Scott D. Ericksen 2026-05-28 | Form 4 | 2026-06-01 | 0001110803-26-000129 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Keith Meister 2026-05-28 | Form 4 | 2026-06-01 | 0001011438-26-000371 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Scott M. Davies 2026-05-29 | Form 4 | 2026-06-01 | 0001110803-26-000130 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Patricia Leckman 2026-06-02 | Form 4 | 2026-06-04 | 0001110803-26-000132 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Patricia Leckman 2026-06-02 | Form 4 | 2026-06-04 | 0001110803-26-000132 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Patricia Leckman 2026-06-02 | Form 4 | 2026-06-04 | 0001110803-26-000132 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Patricia Leckman 2026-06-05 | Form 4 | 2026-06-09 | 0001110803-26-000134 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Patricia Leckman 2026-06-05 | Form 4 | 2026-06-09 | 0001110803-26-000134 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Patricia Leckman 2026-06-05 | Form 4 | 2026-06-09 | 0001110803-26-000134 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Patricia Leckman 2026-06-05 | Form 4 | 2026-06-09 | 0001110803-26-000134 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Patricia Leckman 2026-06-05 | Form 4 | 2026-06-09 | 0001110803-26-000134 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Daniel Skovronsky 2026-06-16 | Form 4 | 2026-06-23 | 0001110803-26-000142 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Scott M. Davies 2026-06-25 | Form 4 | 2026-06-25 | 0001110803-26-000144 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Keith Meister 2026-06-30 | Form 4 | 2026-07-02 | 0001110803-26-000148 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Scott Ullem 2026-06-30 | Form 4 | 2026-07-02 | 0001110803-26-000147 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 06, 2026 vote | Form 8-K | 2026-05-26 | 0001110803-26-000124 | Item 5.07 · say-on-pay result. As reported: 93.5% (votes for as printed: 121,746,792). Filing ↗ |
| 100 | Section 06, 2025 vote | Form 8-K | 2025-05-23 | 0001110803-25-000051 | Item 5.07 · say-on-pay result. As reported: 90.98% (votes for as printed: 115,560,563). Filing ↗ |
| 101 | Section 06, 2024 vote | Form 8-K | 2024-05-20 | 0001110803-24-000030 | Item 5.07 · say-on-pay result. As reported: 86.46% (votes for as printed: 113,511,456). Filing ↗ |
| 102 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 103 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 104 | Section 09b board cost (computed) | Computed | — | computed | Cash 1,057,671 + equity 3,050,190 + all other 0 = 4,107,861, summed across the director compensation table rows.machine: formula: Σ = 4,107,861 |
| 105 | Biogen Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187303 | CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391 |
| 106 | Vertex Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-02 | 0000875320-26-000153 | CEO total compensation as printed in Vertex Pharmaceuticals, Inc.'s own proxy. As printed: 21,144,261. Filing ↗machine: r2 · c13 · span 2942799–2942809 |
| 107 | Intuitive Surgical, Inc., Section 10b CEO total | DEF 14A | 2026-03-13 | 0001035267-26-000023 | CEO total compensation as printed in Intuitive Surgical, Inc.'s own proxy. As printed: 20,997,480. Filing ↗machine: r2 · c48 · span 762289–762299 |
| 108 | Align Technology, Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001097149-26-000023 | CEO total compensation as printed in Align Technology, Inc.'s own proxy. As printed: 19,193,988. Filing ↗machine: r2 · c42 · span 933168–933178 |
| 109 | Jazz Pharmaceuticals plc, Section 10b CEO total | DEF 14A | 2026-06-08 | 0001232524-26-000029 | CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379 |
| 110 | Edwards Lifesciences Corporation, Section 10b CEO total | DEF 14A | 2026-03-26 | 0001099800-26-000015 | CEO total compensation as printed in Edwards Lifesciences Corporation's own proxy. As printed: 17,454,255. Filing ↗machine: r2 · c27 · span 965441–965451 |
| 111 | The Cooper Companies, Inc., Section 10b CEO total | DEF 14A | 2026-02-24 | 0001628280-26-011110 | CEO total compensation as printed in The Cooper Companies, Inc.'s own proxy. As printed: 16,051,141. Filing ↗machine: t120 · r3 · c14 · span 744904–744914 |
| 112 | Hologic, Inc., Section 10b CEO total | DEF 14A | 2025-01-16 | 0001140361-25-001287 | CEO total compensation as printed in Hologic, Inc.'s own proxy. As printed: 15,819,261. Filing ↗machine: r2 · c25 · span 1549664–1549674 |
| 113 | IDEXX Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0000874716-26-000064 | CEO total compensation as printed in IDEXX Laboratories, Inc.'s own proxy. As printed: 14,580,122. Filing ↗machine: span 1576008–1576018 |
| 114 | Waters Corporation, Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149657 | CEO total compensation as printed in Waters Corporation's own proxy. As printed: 13,973,044. Filing ↗machine: r5 · c18 · span 568522–568533 |
| 115 | GeneDx Holdings Corp., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001818331-26-000030 | CEO total compensation as printed in GeneDx Holdings Corp.'s own proxy. As printed: 13,547,219. Filing ↗machine: span 565318–565328 |
| 116 | Agilent Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-02-06 | 0001193125-26-040286 | CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. Filing ↗machine: r3 · c29 · span 1450982–1450992 |
| 117 | Illumina, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149669 | CEO total compensation as printed in Illumina, Inc.'s own proxy. As printed: 11,018,895. Filing ↗machine: r4 · c14 · span 728526–728536 |
| 118 | Bio-Rad Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-03-25 | 0000012208-26-000020 | CEO total compensation as printed in Bio-Rad Laboratories, Inc.'s own proxy. As printed: 7,995,841. Filing ↗machine: r2 · c24 · span 654200–654209 |
| 119 | DexCom, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0001093557-26-000061 | CEO total compensation as printed in DexCom, Inc.'s own proxy. As printed: 7,985,960. Filing ↗machine: span 940364–940373 |
| 120 | Regeneron Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001308179-26-000340 | CEO total compensation as printed in Regeneron Pharmaceuticals, Inc.'s own proxy. As printed: 7,280,549. Filing ↗machine: r3 · c10 · span 3335980–3335989 |
| 121 | West Pharmaceutical Services, Inc, Section 10b CEO total | DEF 14A | 2026-03-12 | 0001104659-26-026778 | CEO total compensation as printed in West Pharmaceutical Services, Inc's own proxy. As printed: 7,190,876. Filing ↗machine: t165 · r7 · c18 · span 1241781–1241790 |
| 122 | Mettler-Toledo International Inc., Section 10b CEO total | DEF 14A | 2026-03-18 | 0001174947-26-000389 | CEO total compensation as printed in Mettler-Toledo International Inc.'s own proxy. As printed: 6,741,212. Filing ↗machine: r2 · c7 · span 643529–643538 |
| 123 | Vestis Corporation, Section 10b CEO total | DEF 14A | 2026-01-08 | 0001628280-26-001322 | CEO total compensation as printed in Vestis Corporation's own proxy. As printed: 3,288,352. Filing ↗machine: r5 · c27 · span 989427–989437 |
| 124 | Section 10a, Edwards Lifesciences Corporation reciprocity | DEF 14A | — | 0001099800-26-000015 | Edwards Lifesciences Corporation names Illumina, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 125 | Section 10a, Hologic, Inc. reciprocity | DEF 14A | — | 0001140361-25-001287 | Hologic, Inc. names Illumina, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 126 | Section 10a, Intuitive Surgical, Inc. reciprocity | DEF 14A | — | 0001035267-26-000023 | Intuitive Surgical, Inc. names Illumina, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 127 | Section 10a, Agilent Technologies, Inc. reciprocity | DEF 14A | — | 0001193125-26-040286 | Agilent Technologies, Inc. names Illumina, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 128 | Section 10a, DexCom, Inc. reciprocity | DEF 14A | — | 0001093557-26-000061 | DexCom, Inc. names Illumina, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 129 | Section 10a, Mettler-Toledo International Inc. reciprocity | DEF 14A | — | 0001174947-26-000389 | Mettler-Toledo International Inc.'s most recent proxy was read; its disclosed peer group does not include Illumina, Inc.. Filing ↗ |
| 130 | Section 10a, Vertex Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0000875320-26-000153 | Vertex Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Illumina, Inc.. Filing ↗ |
| 131 | Section 10a, Align Technology, Inc. reciprocity | DEF 14A | — | 0001097149-26-000023 | Align Technology, Inc. names Illumina, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 132 | Section 10a, West Pharmaceutical Services, Inc reciprocity | DEF 14A | — | 0001104659-26-026778 | West Pharmaceutical Services, Inc's most recent proxy was read; its disclosed peer group does not include Illumina, Inc.. Filing ↗ |
| 133 | Section 10a, GeneDx Holdings Corp. reciprocity | DEF 14A | — | 0001818331-26-000030 | GeneDx Holdings Corp.'s most recent proxy was read; its disclosed peer group does not include Illumina, Inc.. Filing ↗ |
| 134 | Section 10a, Vestis Corporation reciprocity | DEF 14A | — | 0001628280-26-001322 | Vestis Corporation's most recent proxy was read; its disclosed peer group does not include Illumina, Inc.. Filing ↗ |
| 135 | Section 10a, Regeneron Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001308179-26-000340 | Regeneron Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Illumina, Inc.. Filing ↗ |
| 136 | Section 10a, IDEXX Laboratories, Inc. reciprocity | DEF 14A | — | 0000874716-26-000064 | IDEXX Laboratories, Inc. names Illumina, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 137 | Section 10a, Jazz Pharmaceuticals plc reciprocity | DEF 14A | — | 0001232524-26-000029 | Jazz Pharmaceuticals plc's most recent proxy was read; its disclosed peer group does not include Illumina, Inc.. Filing ↗ |
| 138 | Section 10a, Waters Corporation reciprocity | DEF 14A | — | 0001193125-26-149657 | Waters Corporation names Illumina, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 139 | Section 10a, The Cooper Companies, Inc. reciprocity | DEF 14A | — | 0001628280-26-011110 | The Cooper Companies, Inc. names Illumina, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |